Related Experiment Video
Updated: Mar 2, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Atrial Fibrillation in Hypertrophic Obstructive Cardiomyopathy - Antiarrhythmics, Ablation and More!
Gangadhar Malasana1, John D Day2, T Jared Bunch2
1Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Insights
Hypertrophic cardiomyopathy (HCM) patients frequently develop atrial fibrillation (AF). While non-pharmacologic strategies show promise for AF management, long-term effects require study, and anticoagulation remains crucial.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Hypertrophic cardiomyopathy (HCM) is an inherited cardiac sarcomere disease.
- Atrial fibrillation (AF) is a common and serious complication in HCM patients, linked to diastolic dysfunction and left atrial enlargement.
- AF significantly increases mortality, morbidity, and reduces quality of life in HCM.
Purpose of the Study:
- To review current understanding of rhythm control strategies for atrial fibrillation in hypertrophic cardiomyopathy.
- To evaluate the efficacy and safety of pharmacologic and non-pharmacologic approaches for AF in HCM.
- To discuss the implications of AF management in HCM for broader patient populations with hypertensive cardiomyopathy.
Main Methods:
- Review of existing literature on atrial fibrillation management in hypertrophic cardiomyopathy.
- Analysis of pharmacologic antiarrhythmic therapies and non-pharmacologic interventions.
- Discussion of long-term impacts on atrial function and quality of life.
Main Results:
- Antiarrhythmic drugs offer symptomatic relief and reduce AF recurrence but have limited long-term safety data in HCM.
- Non-pharmacologic approaches demonstrate comparable or superior efficacy to medications.
- Rhythm control strategies are often necessary due to the significant impact of AF in HCM.
Conclusions:
- Rhythm control in HCM may offer insights for treating AF in hypertensive cardiomyopathy.
- Long-term effects of non-pharmacologic AF treatments on atrial function in HCM need further investigation.
- Patients with HCM and AF, regardless of rhythm control strategy, face moderate to high thromboembolism risk, necessitating long-term warfarin anticoagulation.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the cardiac sarcomere with an autosomal dominant pattern of inheritance. Patients with HCM are at high risk of developing atrial fibrillation (AF) particularly in the setting of advanced diastolic dysfunction and left atrial enlargement. AF is a marker of increased mortality and morbidity and results in a significant reduction in quality of life. Antiarrhythmic medications improve symptoms and reduce AF recurrence, but few are safe and there exists little data to guide their long-term use in HCM. Non-pharmacologic approaches have emerged and have equal or greater efficacy than pharmacologic approaches. Although these approaches are promising, the long-term impact on atrial function needs to be carefully studied as it may impact quality of life in patients that age in the setting of a progressive diastolic disease disorder. Nonetheless, with the significant impact of AF in HCM, rhythm control strategies are often required. The understanding of rhythm control strategies in HCM, an often rapidly progressive diastolic dysfunction disorder, may provide insight in how to treat the much more prevalent AF patient with hypertensive cardiomyopathy. Regardless of treatment strategy (rhythm or rate control) patients are a moderate to high risk of thromboembolism and until data are available to suggest otherwise require long-term warfarin anticoagulation.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:30Cardiomyopathy II: Dilated Cardiomyopathy